Last reviewed · How we verify
NCT05320497
Transparent Cap-assisted SpyGlass for Biliary Stricture
NA trial testing Transparent cap in Bile Duct Stricture in 10 participants. Status unknown.
10 July 2022
Quick facts
| Lead sponsor | Affiliated Hospital to Academy of Military Medical Sciences |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 10 |
| Start date | 14 April 2022 |
| Primary completion | 10 July 2022 |
| Estimated completion | 30 July 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Transparent cap
Conditions studied
- Bile Duct Stricture — all drugs for Bile Duct Stricture →
- Endoscopic Retrograde Cholangiopancreatography — all drugs for Endoscopic Retrograde Cholangiopancreatography →
- Biliary Disease — all drugs for Biliary Disease →
- Biliary Tract Neoplasms — all drugs for Biliary Tract Neoplasms →
Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Who can join
18 and older, any sex, with Bile Duct Stricture or Endoscopic Retrograde Cholangiopancreatography. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The transparent cap-assisted endoscope has the function of fixing field of view and increasing visual space. It has been widely used in gastrointestinal examination and treatment. In this study, the investigators intend to apply transparent cap-assisted choledochoscopy to endoscopic biliary tract exploration and biopsy to investigate whether transparent cap-assisted choledochoscopy can improve operability, visual field clarity, and biopsy accuracy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05320497
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Affiliated Hospital to Academy of Military Medical Sciences trials
Trials by the same sponsor.
- NCT06986434 — CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differenti · EARLY_PHASE1 · not yet recruiting
- NCT07416682 — CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms · EARLY_PHASE1 · not yet recruiting
- NCT06834529 — CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma · Phase 1, PHASE2 · recruiting
- NCT06152263 — LCI in Chronic Atrophic Gastritis and Early Gastric Cancer · unknown
- NCT05645601 — CAR-NK Targeted CD19 for r/r B-cell Malignancies · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05320497 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital to Academy of Military Medical Sciences
- Last refreshed: 15 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05320497.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing